Compare

CRISPR/$CRSP

1D1W1M3M6MYTD1Y5YMAX

About CRISPR

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Ticker
$CRSP
Sector
Health
Primary listing
NASDAQ
Employees
393
Headquarters
Zug, Switzerland

CRISPR Metrics

BasicAdvanced
$3.9B
-
-$4.75
1.90
-

What the Analysts think about CRISPR

Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
Analyst projections of the future price of CRISPR stock.

Bulls say / Bears say

CASGEVY sales reached $99 million in Q3 2026, up 30% quarter on quarter and nearly sixfold year on year. It is approved in 39 countries, with approvals for younger children widening its potential patient pool. (CRISPR Therapeutics)
In a Phase 1b study of severe hypertriglyceridaemia, CTX310 cut triglycerides by a mean 63% at day 30; earlier Phase 1a data showed lipid reductions lasting a year. These early results offer a potential growth driver beyond CASGEVY. (CRISPR Therapeutics, CRISPR Therapeutics)
Early Phase 1 results for zugo-cel showed response signals in autoimmune diseases, and the company said it had been well tolerated in all 21 patients treated. This gives CRISPR another potentially valuable pipeline avenue, although the evidence is still early. (Investing.com, CRISPR Therapeutics)
The CASGEVY patient journey can be slow: company management said it may take more than six months, and sometimes nine months or longer, from treatment initiation to infusion. That can delay the conversion of patient starts into treated patients and sales. (Stock Analysis)
CRISPR reported $12.7 million in total revenue and a $111.4 million net loss in Q3, despite CASGEVY’s $99 million in sales with Vertex. Commercial growth has yet to deliver profitability for CRISPR. (U.S. Securities and Exchange Commission, Morningstar)
Vertex controls CASGEVY’s global development, manufacturing and commercialisation, and receives 60% of its profits, leaving CRISPR with 40% and limited control over its only marketed therapy. This makes near-term commercial returns dependent on a partner and limits how much of the product’s success CRISPR captures. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.

CRISPR Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

CRISPR Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing CRISPR

Funds
Fund name
Fund size
$CRSP weighting
ARK Genomic Revolution€AAKG
$129M4.97%
ARK Genomic Revolution£ARCG
$129M4.97%
ARK Innovation€ARXK
$294M4.45%
ARK Innovation£ARCK
$294M4.45%
iShares Ageing Population£AGES
$887M0.34%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.